Emcure Pharmaceuticals is currently trading at Rs 943.90, up by 3.95 points or 0.42% from its previous closing of Rs 939.95 on the BSE.
The scrip opened at Rs 954.95 and has touched a high and low of Rs 960.10 and Rs 938.90 respectively. So far 883 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52-week high of Rs 1577.50 on 18-Sep-2024 and a 52-week low of Rs 935.00 on 03-Mar-2025.
Last one week high and low of the scrip stood at Rs 999.50 and Rs 935.05 respectively. The current market cap of the company is Rs 17880.47 crore.
The promoters holding in the company stood at 77.94%, while Institutions and Non-Institutions held 6.92% and 15.14% respectively.
Emcure Pharmaceuticals has entered into the daily supplements space with the expansion of its Arth range. Arth offers a wide range of supplements that harness the power of ancient Indian herbs like Brahmi, with the precision of modern science to address key health concerns that are often overlooked.
As an initiative within its broader efforts for quality and women's health education, Emcure has partnered with acclaimed actor and women’s health advocate Vidya Balan as the brand ambassador for its Arth range. As a part of the association, Vidya will spotlight three key products from the Arth range: Intimate Care to soothe itchiness and dryness in intimate areas, Sleep Support Gummies for blissful and quality sleep; Brain Fog Aid to improve focus and support cognition.
Emcure Pharmaceuticals is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: